$AbCellera Biologics(ABCL)$ Under the terms of the agreement, Moderna will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Moderna downstream clinical and commercial milestone payments and royalties on net sales of products. Look at it this way. Volume is now nearly 13 MILLION SHARES , whereas average is 2 MILLION so say 7 times usual trades. IF you can be GREEN on A red day !! Then it must be a very good company. Well I am " all in" on this one so pray to god that it is as good as I think.
精彩评论